Immunotherapy plus chemoradiation shows promise in head and neck cancer trial
NCT ID NCT05213884
First seen May 06, 2026 · Last updated May 07, 2026 · Updated 1 time
Summary
This study tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy and radiation could help people with advanced head and neck cancer. 39 adults with inoperable or surgery-refusing stage III-IVb cancer received the combination. The goal was to see if it improved how long patients lived without the cancer growing or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Chongqing University Three Gorges Hospital
Wanzhou, Chongqing Municipality, 404100, China
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, 646000, China
Conditions
Explore the condition pages connected to this study.